{"id":"mebicar","rwe":[{"pmid":"38164833","year":"2023","title":"Evaluation of the anxiolytic activity of dry extract of Patrinia scabiosifolia under acoustic stress.","finding":"","journal":"European review for medical and pharmacological sciences","studyType":"Clinical Study"},{"pmid":"37622495","year":"2023","title":"TREATMENT OPTIMIZATION IN MANAGEMENT OF COMBINED PATHOLOGY - ARTERIAL HYPERTENSION AND POST-COVID SYNDROME IN ELDERLY PATIENTS.","finding":"","journal":"Wiadomosci lekarskie (Warsaw, Poland : 1960)","studyType":"Clinical Study"},{"pmid":"32909641","year":"2020","title":"Effectiveness of psychopharmacotherapy in psoriasis patients with associated anxiety and depression.","finding":"","journal":"Dermatologic therapy","studyType":"Clinical Study"},{"pmid":"29920498","year":"2018","title":"Preventive Effect of Mebicar and Ginsenoside Rg1 on Neurobehavioral and Immunological Disruptions Caused by Intermittent Unpredictable Stress in Mice.","finding":"","journal":"Neuroimmunomodulation","studyType":"Clinical Study"},{"pmid":"29265088","year":"2017","title":"[An experience of using mebicar in patients with autonomic dysfunction associated with anxiety disorder].","finding":"","journal":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anxiety","category":"indication"},{"label":"Attention deficit hyperactivity disorder","category":"indication"},{"label":"Analgesics","category":"pharmacology"},{"label":"Anti-Anxiety Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"adaptol","offLabel":[],"synonyms":["mebicar","mebikar","adaptol"],"timeline":[],"approvals":[],"brandName":"Adaptol","ecosystem":[{"indication":"Anxiety","otherDrugs":[{"name":"alprazolam","slug":"alprazolam","company":"Pharmacia And Upjohn"},{"name":"chlordiazepoxide","slug":"chlordiazepoxide","company":"Valeant Pharm Intl"},{"name":"chlormezanone","slug":"chlormezanone","company":""},{"name":"clorazepate","slug":"clorazepate","company":"Recordati Rare"}],"globalPrevalence":301000000},{"indication":"Attention deficit hyperactivity disorder","otherDrugs":[{"name":"amfetamine","slug":"amfetamine","company":"Ucb Inc"},{"name":"atomoxetine","slug":"atomoxetine","company":"Lilly"},{"name":"clonidine","slug":"clonidine","company":"Boehringer Ingelheim"},{"name":"dexamfetamine","slug":"dexamfetamine","company":"Ucb Inc"}],"globalPrevalence":130000000}],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your brain is a busy city with many different streets and intersections. Adaptol helps to calm down the traffic by adjusting the flow of chemical messengers, or neurotransmitters, that carry signals between different parts of the brain. This can help to reduce anxiety and improve focus.","oneSentence":"Adaptol is thought to work by modulating neurotransmitter activity in the brain.","technicalDetail":"Adaptol is believed to exert its effects through interaction with neurotransmitter systems, although the specific mechanisms and receptors involved are not well-characterized."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4861","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=mebicar","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:31:00.642748","biosimilars":[],"competitors":[],"genericName":"mebicar","indications":{"approved":[{"name":"Anxiety","source":"DrugCentral","snomedId":48694002,"regulator":"FDA","usPrevalence":40000000,"globalPrevalence":301000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2022"},{"name":"Attention deficit hyperactivity disorder","source":"DrugCentral","snomedId":406506008,"regulator":"FDA","usPrevalence":10000000,"globalPrevalence":130000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Psychiatry, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"CHEBI":"CHEBI:136038","UMLSCUI":"C0065835","ChEMBL_ID":"CHEMBL3707390","KEGG_DRUG":"D10508","DRUGBANK_ID":"DB13522","PUBCHEM_CID":"122282","MESH_SUPPLEMENTAL_RECORD_UI":"C015979"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":34,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2023 Dec","pmid":"38164833","title":"Evaluation of the anxiolytic activity of dry extract of Patrinia scabiosifolia under acoustic stress.","journal":"European review for medical and pharmacological sciences"},{"date":"2023","pmid":"37622495","title":"TREATMENT OPTIMIZATION IN MANAGEMENT OF COMBINED PATHOLOGY - ARTERIAL HYPERTENSION AND POST-COVID SYNDROME IN ELDERLY PATIENTS.","journal":"Wiadomosci lekarskie (Warsaw, Poland : 1960)"},{"date":"2020 Nov","pmid":"32909641","title":"Effectiveness of psychopharmacotherapy in psoriasis patients with associated anxiety and depression.","journal":"Dermatologic therapy"},{"date":"2018","pmid":"29920498","title":"Preventive Effect of Mebicar and Ginsenoside Rg1 on Neurobehavioral and Immunological Disruptions Caused by Intermittent Unpredictable Stress in Mice.","journal":"Neuroimmunomodulation"},{"date":"2017","pmid":"29265088","title":"[An experience of using mebicar in patients with autonomic dysfunction associated with anxiety disorder].","journal":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Adaptol, also known as mebicar, is a small molecule drug with unknown drug class and target. It is used to treat anxiety and attention deficit hyperactivity disorder (ADHD). The commercial status of Adaptol is unclear, and it may be patented or have generic manufacturers. Key safety considerations are not well-documented. Further research is needed to fully understand its pharmacology and clinical use.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}